Adverse events of targeted therapies approved for women's cancers

Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle inhibitors for hormone receptor positive breas...

Descripción completa

Detalles Bibliográficos
Autores principales: Saint-Ghislain, Mathilde, Levenbruck, Chloé, Bellesoeur, Audrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721120/
https://www.ncbi.nlm.nih.gov/pubmed/35024412
http://dx.doi.org/10.1016/j.ijwd.2021.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721120/
https://www.ncbi.nlm.nih.gov/pubmed/35024412
http://dx.doi.org/10.1016/j.ijwd.2021.10.006

Ejemplares similares